Research graph
References from Circulating tumor cells predict early skeletal-related events in patients with bone metastases from breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical features of metastatic bone disease and risk of skeletal morbidity
10.1158/1078-0432.ccr-06-0931 · 2006 · External reference
Chapter 82: medical treatment for bone metastases
2014 · External reference
Skeletal complications of malignancy
10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · 1997 · External reference
Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management
10.1016/j.jbo.2018.10.004 · 2019 · External reference
Latent bone metastasis in breast cancer tied to Src-dependent survival signals
10.1016/j.ccr.2009.05.017 · 2009 · External reference
Models, mechanisms and clinical evidence for cancer dormancy
10.1038/nrc2256 · 2007 · External reference
Effect of bisphosphonates on pain and quality of life in patients with bone metastases
2009 · External reference
Health-related quality of life among patients with breast cancer receiving zoledronic acid for bone metastases
2004 · External reference
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
2014 · External reference
Denosumab compared with zoledronic acid for treatment of bone metastases in advanced breast cancer
10.1200/jco.2010.29.7101 · 2010 · External reference
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
10.1056/nejmoa040766 · 2004 · External reference
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
10.1016/s1470-2045(14)70069-5 · 2014 · External reference
Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer
10.1093/annonc/mdp262 · 2010 · External reference
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer
10.1007/s10549-010-0981-1 · 2010 · External reference
Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival
10.1016/j.ejca.2012.05.007 · 2012 · External reference
Circulating tumor cells in patients with recurrent or metastatic head and neck carcinoma: prognostic and predictive significance
10.1371/journal.pone.0103918 · 2014 · External reference
Analysis of circulating tumor cells in prostate cancer patients at PSA recurrence and review of the literature
2016 · External reference
Circulating Tumor Cell as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial
10.1177/030089161109700610 · 2011 · External reference
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
10.1158/1078-0432.ccr-05-2821 · 2006 · External reference
Molecular Interplay between dormant bone marrow-resident cells (BMRCs) and CTCs in breast cancer
10.3390/cancers12061626 · 2020 · External reference
Biological effects of cyclin-dependent kinase inhibitors Ribociclib, Palbociclib and Abemaciclib on breast cancer bone microenvironment
10.3390/ijms23052477 · 2022 · External reference
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): international expert consensus paper
10.1016/j.critrevonc.2018.12.004 · 2019 · External reference
AR expression in breast cancer CTCs associates with bone metastases
10.1158/1541-7786.mcr-17-0480 · 2018 · External reference
Sex differences and bone metastases of breast, lung and prostate cancers: do bone homing cancers favors feminized bone marrow?
10.3389/fonc.2017.00163 · 2017 · External reference
Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions
10.1186/s13578-023-01171-8 · 2023 · External reference
Dynamic changes of Receptor activator of nuclear factor-kB expression in circulating tumor cells during denosumab predict treatment effectiveness in metastatic breast cancer
10.1038/s41598-020-58339-2 · 2020 · External reference
